Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B2AN-SNS: Entresto vs ACE inhibitor or AT1 receptor blocker on sympathetic nervous system activity in heart failure
2016-001124-66Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Sympathetic neural activity by microneurography. Started Mar 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2016-001124-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001124-66.